

The Cardiac MPS: Collaboration with Simula and Future Applications

Kevin E. Healy

University of California, Berkeley

Jan Fandrianto and Selfia Halim Distinguished Professor

Department of Bioengineering
Department of Materials Science and Engineering

Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.



Affiliation/Financial Relationship

- Grant/Research Support
- Consulting Fees/Honoraria
- Major Stock Shareholder/Equity
- Royalty Income
- Ownership/Founder
- Intellectual Property Rights
- Other Financial Benefit

Company



- None - Federal Only
- Abbott Vascular, Valitor
- CaridoRegenX, Valitor, Organos
- UCB
- CaridoRegenX, Valitor, Organos
- CaridoRegenX, Valitor, Organos
- Speaking Honoraria

Microphysiological Systems Applications

Safety Pharmacology




Organ Storage & Transport




Countermeasures & Threat Detection



Metabolism



Biomaterials Therapy



Toxins



Gene Editing



Drug-induced Arrhythmias are a Major Safety Concern



All drugs screened for proarrhythmia risk prior to first-in-human trials




Torsade de Pointes (TdP)

State-of-the-Art Practice Not Predictive of Drug Risk

Heart Disease is a **Tissue** Level Disease

State-of-the-Art Practice (**2D plate biology**) Not Predictive of Drug Risk


Heart Organoid



Ma, Z., et al., *Nature Comm.*, 14, 6:7413 (2015)

Drug Screening on fetal development


3D Cardiac Tissue



Ma, Z. et al., *Biomaterials* 35(5), 1367 (2014)
Ma, Z., & Huebsch, N., et al.,
Nature Biomedical Engineering, 2, 955-967 (2018)

Genetic Disease Modeling


Cardiac MPS Tissue Chip



Charrez, B., et al. *Clin. Transl. Sci.* 14, 1155 (2021)
Mathur, A., Loskill, P., et al., *Scientific Reports*, 5:8883 (2015)

Safety pharmacology and 'clinical trials'

Microphysiological Systems




**Microfabrication
Technology**



+



Microphysiological Systems (MPS)



**Human induced pluripotent
stem cells (hiPSC)**




**Carries patient's genetics
healthy or diseased**

- **Biofabricated tissue**
- **Clinically relevant**
- **Phenotypic tissue model**
- **Population-based**


Cardiac Microphysiological System - Heart Micromuscle

Multiplexed cardiac MPS

Multiplexed tissue chambers per device
Integrated pacing electrodes








3D cardiac microtissues



Biomarker
Mass spectrometry


Reporter cell lines for
real-time live cell imaging

Flexible pillars for
force measurement





Metrics

- Spontaneous and externally paced beating
- Voltage and calcium transients
- Beat rate, action potential duration (QT proxy), beat shape metrics, arrhythmic events



Cardiac Microphysiological System

What is the minimal tissue or organoid size to assist in drug discovery?



Cell channel mimics perimysial fiber spacing


Separate media and cell channels

μ -pores between media and cell channels - “endothelial barrier”

Convective transport in media channels

Diffusive transport to tissue (no shear)


Physiologically relevant tissue to media volumes






Physiological Platform for Human Myocardium-on-a-Chip





How Important is Structure?



Promotes cell maturity






- 3D cardiac micromuscle
- Organized beating
- Coordinated contraction magnitude & direction




- 2D classic cell culture
- Disorganized beating
- Variable contraction magnitude & direction


Cardiac Chip - Realtime Clinically Relevant Measurements




Beat Rate (bpm) & Contraction Force





Action Potential Duration ~ QT



Calcium Dynamics



ATP Sourcing Changes and Mitochondrial Development in Postnatal Cardiomyocytes




*** Concurrent with postnatal hypertrophy, cardiomyocytes switch from glycolysis to fatty acid oxidation as primary means for making ATP**


*** Switch back to glycolysis during heart failure**

Hypothesis: switching ATP source will enhance maturation of hiPSC-CM in Cardiac MPS



Maturation Media Enhances Cardiac MPS Electrophysiology & Inotropy






In Silico Maturation of Cardiac MPS Data - Prediction of Adult Drug Response



simula



Mechanism of Action



Adult Predictions

- ✦ **Will** compounds change the behavior of adult cardiac cells?
- ✦ What are the *mechanisms* of change?
- ✦ What is the predicted effect *in vivo*?

Tveito, A., Jæger, K.H., Huebsch, N., Charrez, B., Edwards, A.G., Wall, S. & Healy, K.E. Inversion and computational maturation of drug response using human stem cell derived cardiomyocytes in microphysiological systems. *Scientific reports* **8**, 1-14 (2018).

Jæger, K.H., Charwat, V., Charrez, B., Finsberg, H., Maleckar, M.M., Wall, S., Healy, K.E. & Tveito, A. Improved computational identification of drug response using optical measurements of human stem cell derived cardiomyocytes in microphysiological systems. *Frontiers in pharmacology* **10**, 1648 (2020).

Charrez, B., Charwat, V., Siemons, B.A., Goswami, I., Sakolish, C., Luo, Y.S., Finsberg, H., Edwards, A.G., Miller, E.W., Rusyn, I. & Healy, K.E. Heart Muscle Microphysiological System for Cardiac Liability Prediction of Repurposed COVID-19 Therapeutics. *Front Pharmacol* **12**, 684252 (2021).


Charrez, B., Charwat, V., Siemons, B., Finsberg, H., Miller, E.W., Edwards, A.G. & Healy, K.E. In vitro safety “clinical trial” of the cardiac liability of drug polytherapy. *Clinical and translational science* **14**, 1155-1165 (2021).

Jæger, K.H., Charwat, V., Wall, S., Healy, K.E. & Tveito, A. Identifying drug response by combining measurements of the membrane potential, the cytosolic calcium concentration, and the extracellular potential in microphysiological systems. *Frontiers in pharmacology* **11**, 569489 (2021).




Huebsch, N., Charrez, B., Neiman, G., Siemons, B., Boggess, S.C., Wall, S., Charwat, V., Jaeger, K.H., Cleres, D., Telle, A., Lee-Montiel, F.T., Jeffreys, N.C., Deveshwar, N., Edwards, A.G., Serrano, J., Snuderl, M., Stahl, A., Tveito, A., Miller, E.W. & Healy, K.E. Metabolically driven maturation of human-induced-pluripotent-stem-cell-derived cardiac microtissues on microfluidic chips. *Nat Biomed Eng* **6**, 372-388 (2022).

Charwat, V., Charrez, B., Siemons, B.A., Finsberg, H., Jæger, K.H., Edwards, A.G., Huebsch, N., Wall, S., Miller, E., Healy, K.E. & Tveito, A. Validating the Arrhythmogenic Potential of High-, Intermediate-, and Low-Risk Drugs in a Human-Induced Pluripotent Stem Cell-Derived Cardiac Microphysiological System. *ACS Pharmacology & Translational Science* (2022).




In Silico Maturation of Cardiac MPS Data - Prediction of Adult Drug Response



Case Studies - *Eliminating False Positives & Negatives*




Model	IC ₅₀ (nM)	IC ₅₀ /Avg. ETPC _{unbound}
2D CMs	169 ± 24	2.2 ± 0.45
Cardiac MPS	960.6 ± 187	18.1 ± 3.5



- ✓ Clinical response
- ✓ Go-no-Go decisions






Modeling the Effect of Maturation Media on Ion Currents and Calcium Handling




Case Studies - Arrhythmia Classification

FDA E14 Guidance


Upper 95% confidence bound mean $\Delta\Delta QT_c < 10$ ms



Cardiac MPS Predicts Clinical Arrhythmias & Drug Risk



Cardiac MPS Predicts Clinical Arrhythmias & Drug Risk




Clinical Trial Case Study - *HCQ + AZM to treat COVID-19*

Goal: Perform a mock COVID drug QT/QTc screen in the cardiac chip

Typical QT/QTc Study Costs \$2-4 Million

- Usually 50-60 subjects per treatment arm
- Required to assess a new drug's potential to delay cardiac repolarization

Dose-Escalation Workflow



International Journal of Antimicrobial Agents

Available online 20 March 2020, 105949

In Press, Journal Pre-proof



Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Philippe Gautret ^{a, b, \$}, Jean-Christophe Lagier ^{a, c, \$}, Philippe Parola ^{a, b}, Van Thuan Hoang ^{a, b, d}, Line Meddeb ^a, Morgane Mailhe ^a, Barbara Doudier ^a, Johan Courjon ^{e, f, g}, Valérie Giordanengo ^h, Vera Esteves Vieira ^a, Hervé Tissot Dupont ^{a, c}, Stéphane Honoré ^{i, j}, Philippe Colson ^{a, c}, Eric Chabrière ^{a, c}, Bernard La Scola ^{a, c}, Jean-Marc Rolain ^{a, c}, Philippe Brouqui ^{a, c}, Didier Raoult ^{a, c}





Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Mandeep R Mehra, Sapan S Desai, Frank Ruschitzka, Amit N Patel

Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis


Clinical Trials in a Dish for COVID-19 Drug Repurposing

In vitro safety 'clinical trial' workflow




The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin


Chorin, E., et al., *The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin*. 2020.







Clinical Trial Protocol on Chip



Clinical Trials in a Dish for COVID-19 Drug Repurposing



Clinical Trials in a Dish for COVID-19 Drug Repurposing




This research was supported by

NIH-NIDDK 1UG3DK120004, NIH-NCATS UH3TR000487, NIH-NHLBI R01HL096525, NIH-NHLBI R01HL130417, California Inst. of Regenerative Medicine, and FDA (U01FD005978 CERSI)

University of California, Berkeley

Prof. Evan Miller Prof. B. Rubinsky Prof. C. Dames
Prof. Andreas Stahl Prof. Costas Grigoropoulos
Dr. Gabriel Neiman
Dr. Verena Charwat
Dr. Berenice Charrez
Dr. Ishan Goswami
Dr. Matt Powell-Palm
Prof. Nathaniel Huebsch (Wash U.)
Prof. Zhen Ma (Syracuse U.)
Brian A. Siemons
Dr. Steven Boggess



UC San Francisco & Gladstone Inst. Cardiovascular Disease

Prof. Bruce Conklin Prof. M. Hebrok Prof. E. Hsiao
Prof. Holger Willenbring




University of California
San Francisco



Forskningrådet
The Research Council of Norway


Thank You



Cardiac Micromuscle - Microphysiological System


A hybrid system with on chip electrical and mechanical measurements

Real Time Sampling



Blood vessel-like channels - 50 μ m (biomarkers)

Pillars measure contraction force



Heart micromuscle
150 μ m x 1000 μ m

Barriers allow
diffusive transport
2 μ m x 2 μ m x 40 μ m